Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > anyone notice this in the sub-head of the release last night

<< Previous

Bullboard Posts

Next >>

Comment by MrMugsyon Feb 18, 2021 8:31am

167 Views

Post# 32593688

RE:anyone notice this in the sub-head of the release last night

MikeStock wrote: I haven't seen this on any other of their releases:

/NOT FOR DISTRIBUTION OR DISSEMINATION INTO THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES/

I believe it relates to the shelf prospectus as written ...

The Offered Securities will be offered in the provinces of British Columbia, Alberta, Saskatchewan, Manitoba and Ontario, pursuant to a prospectus supplement to be dated on or about February 19, 2021 to the Company's base shelf prospectus dated January 12, 2021 (the "Prospectus") and elsewhere in compliance with applicable securities laws.

<< Previous

Bullboard Posts

Next >>

Who, why, and what of the great "Crypto Surge"